Navigation Links
Immune Targeting Systems and WCCT Global Announce a New Influenza A H1N1 Virus to Support the Experimental Human Viral Challenge Model
Date:8/18/2014

ion and other standard containment provisions to accommodate this valuable research model and ensure the safety and comfort of the volunteers and staff. 

Benjamin Chen, PhD, CEO of Immune Targeting Systems said, "We are very excited that WCCT Global has taken over the ownership of this important clinical research tool and are confident that they will use the virus to help support the development of new vaccines and antiviral drugs".  Kenneth Kim, MD, CEO of WCCT Global said, " The capability to carry out the experimental influenza challenge model in conjunction with our deep-seated expertise in anti-viral drug development will surely be of great interest to our sponsors. This new capability combined with our Full Service Global capabilities, specialized influenza project teams, and deep scientific knowledge allows WCCTG to manage vaccine and antiviral development programs from First in Man through NDA submission."

More about Immune Targeting Systems

Immune targeting Systems, Ltd develops T-cell vaccines to highly mutated viruses and to cancers. The company's lead product  Flunisyn™ vaccine has been shown in three clinical studies to stimulate the production of T-cells that recognise and destroy influenza-infected cells. Flunisyn™  is a pan-influenza A vaccine applicable to multiple influenza strains without the need to be re-manufactured for each influenza season or pandemic outbreak.  The Company is also advancing the development of two other product candidates: a therapeutic Hepatitis B vaccine for chronic hepatitis B and a cancer vaccine for solid tumours. ITS is supported by Novartis Venture fund, Truffle Capital, HealthCap, Esperante Ventures and SME wholesale Finance.

More about WCCT Global

WCCT Global is a multi-site, full service pharmaceutical contract res
'/>"/>

SOURCE WCCT Global
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
2. Novimmune Reports Successful Completion of Phase I trial for NI-0101
3. Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin
4. UMD Researcher Helps Arm the Immune System to Fight Cancer
5. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
6. BHI Elects MedImmunes Reg Seeto, M.D. to Board of Directors
7. Global Autoimmune Disease Diagnostics Market
8. NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sectors Recent Market Decline
9. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
10. Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results
11. Unilife Announces Supply Agreement with MedImmune for Wearable Injectable Drug Delivery Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 Every year ... research to fight heart disease.  Nevertheless, year after year ... ElectroCardioGrams (EKG) as the first test to determine the ... have chest pain or not, even though that technology ... despite the fact that doctors know, (while most patients ...
(Date:2/26/2015)... Mass. , Feb. 26, 2015  Spring ... novel therapeutics for the treatment of Hepatitis B ... the closing of a $22 million financing. Funds ... SB 9200, a novel, broad spectrum antiviral agent ... nucleic acid hybrid (SMNH) chemistry platform, into Phase ...
(Date:2/26/2015)... 26, 2015  Lyric Pharmaceuticals Inc. today announced the ... $20.4 million. The financing, co-led by RiverVest Venture Partners, ... Aperture Venture Partners. Lyric is a ... Wurtman , M.D., M.B.A., President & Chief Executive Officer ... Officer.  In 2014, Lyric closed a seed financing round ...
Breaking Medicine Technology:National Heart Health Month In February 2Spring Bank Pharmaceuticals Completes $22 Million Financing 2
... NEW YORK, Sept. 13, 2011 IMMUNE ... based Therapeutics for the treatment of inflammatory diseases and ... M.D., Ph.D., to the position of Chief Medical Officer.  ... pivotal  role in the development of Bertilimumab, IMMUNE,s phase ...
... DIEGO, Sept. 13, 2011 Sequenom, Inc. (NASDAQ: ... solutions, today announced the Company,s participation at the UBS Global ... in New York City September 19-21, 2011. ... Development, will present on Monday, September 19, 2011 beginning at ...
Cached Medicine Technology:IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 2IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 3Sequenom Announces Participation at UBS Global Life Sciences Conference 2
(Date:2/27/2015)... 27, 2015 The decision to relocate US ... facilities and to make camp more accessible to campers outside ... a Contact Football Camp. The fields are in premier condition ... country,” states Mike de Surville, vice president of US Sports ... of experienced coaches with the passion to create a program ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 RDI-Engineering will ... Mind: Pi Day event on March 14, at Moreno ... services, demonstrations on how to use engineering software and ... will be hosted by Moreno Valley College’s Upward Bound ... Success Center (SSC) in hopes to encourage students to ...
(Date:2/27/2015)... 27, 2015 Is it reasonable – and ... practices and games, and possible to do so without causing ... sports might be at high risk for concern and could ... the issues being addressed by two introductory bills, Int. ... hearing last month in New York City. More specifically, ...
(Date:2/27/2015)... February 27, 2015 Many mattresses ... people’s health. Mercola.com has introduced organic cotton mattresses ... toxic flame retardant chemicals. Dr. Mercola’s Healthy Home ... and better materials. Organic cotton is significantly less ... organic bedding products are made by Naturepedic and ...
(Date:2/27/2015)... According to a Feb. 12, 2015 news release ... treat cancer by killing cancer stem cells, has received orphan ... for use in the treatment of mesothelioma.* According to the ... encourage the development of drugs for the treatment of rare ... decision,” said Melinda Helbock, Founder of The Law Office of ...
Breaking Medicine News(10 mins):Health News:US Sports Camps Football Camps Announce New Contact Football Camp Northeast Location 2Health News:RDI-Engineering Participates in STEM”U”LATE Your Mind Event to Host Educational Exhibition 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 3Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 2Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 3
... March 23 (HealthDay News) -- A new study helps ... drug therapy. Researchers at the Massachusetts General Hospital ... non-small cell lung cancer, the leading cause of cancer ... with resistance. They also confirmed resistance-related genetic changes ...
... Concordia University have pioneered a computer-based method to detect ... that may open a window on the brain,s electrical ... Detection of Epileptic Seizures," presented at the annual meeting ... the very successful application of this new seizure-detection method. ...
... in French . The human brain loses 5 ... 90 years old. While some cells are lost, the brain is ... results of her most recent clinical study published today in the ... Sylvie Belleville, PhD in neuropsychology, the principal author of this study ...
... will convene in Chicago this week to present new ... detect, treat, prevent and cure osteoarthritis (OA), which affects ... the Segal North American Osteoarthritis Workshop (SNOW) on March ... as those that follow joint trauma, obesity and the ...
... who take statin drugs commonly used to lower cholesterol ... their cancer return than patients who do not take ... March issue of the International Journal of Radiation OncologyBiologyPhysics, ... Oncology (ASTRO). , In the study, 1,681 men with ...
... March 22 (HealthDay News) -- Trauma injury patients who arrive ... no more likely to die than those who arrive on ... contrast with previous research that said patients with health emergencies ... they arrive at the hospital at night or on weekends. ...
Cached Medicine News:Health News:Lung Cancer Evolves With Treatment, Study Finds 2Health News:New way to detect epileptic seizures 2Health News:Subjects at risk of Alzheimer's may now be able to delay the onset of their first symptoms 2Health News:Researchers explore new treatments to end OA 2Health News:Trauma Patients Seem More Likely to Survive on Weekends 2
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
Medicine Products: